Collectively, we provide a novel redox‐dependent mechanism in the pathogenesis of LAM and propose that Glrx may be a beneficial strategy for the treatment of LAM or other TSC‐related diseases. The gene discussed is GLRX; the disease is lymphangioleiomyomatosis.